MNTA: M118 Phase 2B trial question Would this trial be regristrational, and if not why? It certainly sounds like the trial would be sufficiently large, and the endpoint will be suitable. I assume they have decided on a dose / schedule. Are there any other variables I am missing?
Market Data 
Markets
AI
